| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30079096 | HIV | ENSG00000180739.15 | protein_coding | S1PR5 | No | No | 53637 | Q9H228 |
| TVIS20020750 | HPV | ENSG00000180739.15 | protein_coding | S1PR5 | No | No | 53637 | Q9H228 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | S1PR5 |
|---|---|
| DrugBank ID | DB12612 |
| Drug Name | Ozanimod |
| Target ID | BE0002432 |
| UniProt ID | Q9H228 |
| Regulation Type | agonist |
| PubMed IDs | 31492652; 28398597; 29125718 |
| Citations | Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdova E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.@@Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA: Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.@@Tran JQ, Hartung JP, Tompkins CA, Frohna PA: Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator. Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640. doi: 10.1002/cpdd.409. Epub 2017 Nov 10. |
| Groups | Approved; Investigational |
| Direct Classification | Phenyloxadiazoles |
| SMILES | CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3707247 |
